CD44 as a Prognostic Marker in Rhabdomyosarcoma
Author Information
Author(s): Humphrey G, Hazel D L, MacLennan K, Lewis I
Primary Institution: Department of Paediatric Oncology and ICRF Cancer Medicine Research Unit, St James's University Hospital
Hypothesis
The study aims to evaluate the role of the standard isoform of CD44 in predicting the clinical behaviour of rhabdomyosarcoma.
Conclusion
The expression of CD44 is correlated with better prognosis in rhabdomyosarcoma patients.
Supporting Evidence
- Eleven of 20 favourable histology tumours were positive for CD44 compared with one of seven unfavourable tumours.
- Eleven of 12 patients with CD44-positive tumours are alive in first remission compared with five of 15 CD44-negative tumours.
Takeaway
This study found that a protein called CD44 can help doctors predict how well patients with a certain type of cancer, rhabdomyosarcoma, will do.
Methodology
Immunohistochemical analysis of CD44 was performed using antibodies, with labelling reported blind to histological type and outcome.
Limitations
Larger studies are required for multivariate analysis.
Statistical Information
P-Value
0.001
Statistical Significance
p=0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website